AB Science (AB.PA) Release: Masitinib Treatment of Progressive Multiple Sclerosis Publication in BMC Neurology  
6/13/2012 10:36:23 AM

PARIS--(BUSINESS WIRE)--AB Science SA (Paris:AB)(NYSE-Euronext-FR0010557264-AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors, announces the publication of results from the human phase 2 study of masitinib carried-out in the treatment of progressive multiple sclerosis. The article, ‘Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study’, is freely accessible online from BioMed Central's peer-reviewed journal BMC Neurology (